MACROPA highly stable chelator of Radium-223 and functionalization attempts for targeted treatment of cancer
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
D Abou, N Thiele, A Villmer, N Gustche, F Escorcia…
2020
jnm.snmjournals.org
587 Objectives: Radium-223 dichloride was approved as the first alpha particle emitting radionuclide therapy in 2013. It demonstrated treatment efficiency in castrate resistant prostate cancer. Yet, 223 RaCl 2 does not accumulate directly in cancerous tissues but rather to sites associated with elevated bone turnover, which is not sufficient to trigger an effective therapeutic response for the complete eradication of bone metastases (1). To specifically target cancerous cells, it is essential to re-engineer Radium-223 alpha therapy …
